

- of a novel 2, 3-diacyl-trehalose-2'-sulfate (SL-IV) antigen for case finding and diagnosis of leprosy and tuberculosis. *Res. Microbiol.* **141** (1990) 679–694.
2. DAFFÉ, M., LACAVE, C., LANÉELLE, M.-A. and LANÉELLE, G. Structure of the major triglycosyl phenol phthiocerol of *Mycobacterium tuberculosis* (strain Canetti). *Eur. J. Biochem.* **167** (1987) 155–160.
 3. DAVID, H. L., LÉVY-FRÉBAULT, V. and THOREL, M. F. *Méthodes de Laboratoire pour Microbiologie Clinique*. Commission des Laboratoires de Reference et d'Expertise de l'Institut Pasteur, eds. Paris: Institut Pasteur, 1989.
 4. DAVID, H. L., MARÓJA, M. F. and CRUAUD, P. Quantitative relationship between anti-PGL-1-specific antibody levels and the lepromin reaction. *Int. J. Lepr.* **59** (1991) 332–334.
 5. FANDINHO, F. C. O., SALEM, J. I., GONTIJO-FILHO, P. P., MARÓJA, M. F. and DAVID, H. L. Mycobacterial flora of the skin in Leprosy. *Int. J. Lepr.* **59** (1991) 569–575.
 6. GRANGE, J. M. Environmental mycobacteria and BCG vaccination. *Tubercle* **67** (1986) 1–4.
 7. LEMASSU, A., LANÉELLE, M.-A. and DAFFÉ, M. Revised structure of a trehalose-containing glycolipid of *Mycobacterium tuberculosis*. *FEMS Microbiol. Lett.* **78** (1991) 171–176.
 8. PAPA, F., CRUAUD, P. and DAVID, H. L. Antigenicity and specificity of selected glycolipid fractions from *Mycobacterium tuberculosis*. *Res. Microbiol.* **140** (1989) 569–578.
 9. SALEM, J. I., GONTIJO-FILHO, P., LÉVY-FRÉBAULT, V. and DAVID, H. L. Isolation and characterization of mycobacteria colonizing the healthy skin. *Acta Leprol.* **7** Suppl. 1 (1989) 18–20.
 10. SALEM, J. I., MARÓJA, M. F., CARVALHO, F. F., LIMA, M. O. and FEUILLET, A. Mycobacteria other than tubercle bacilli in sputum specimens from patients in Manaus (Amazonia, Brazil). *Acta Amazonica* **19** (1989) 349–354.
 11. STANFORD, J. L., SHIELD, M. J. and ROOK, G. A. W. How environmental mycobacteria may predetermine the protective efficiency of BCG. *Tubercle* **62** (1981) 55–62.

Subcorneal Pustular Dermatitis in Type 2 Lepra Reaction

TO THE EDITOR:

A 46-year-old male was diagnosed to have lepromatous leprosy in July 1990, based on clinical and histopathological features and by demonstration of acid-fast bacilli in slit-skin and earlobe smears. There were multiple, shiny, infiltrated macules, plaques and nodules distributed bilaterally and symmetrically on the trunk, limbs and face. The bacterial index (BI) was 6+ (Ridley-Jopling scale) and the morphological index (MI) was 40%. Routine laboratory tests on blood, urine and stools were normal. He was treated with dapsone, rifampin and clofazimine as recommended by the World Health Organization (WHO) for multibacillary leprosy. While on treatment he developed features of type 2 lepra reaction characterized by intermittent high fever, anorexia, neuralgia and multiple erythema nodosum leprosum (ENL) lesions on the front of his legs, face and forearms. Along with these, he also developed numerous pin-head to pea-sized, superficial, oval flaccid pustules on his limbs, buttocks and chest. On the buttocks they

were arranged in a serpiginous pattern, while on the arms they remained discrete (Figs. 1 and 2). These pustules were independent of the ENL lesions. Each pustule dried up and desquamated in 5 to 7 days leaving faint hyperpigmentation, but fresh crops of pustules continued to erupt along with the features of systemic toxicity. Blood tests done at this time revealed leukocytosis (12,000 cells/cubic mm) with a predominance of neutrophils (70%) in the differential leukocyte count. ESR was 80 mm first hour (Westergren). Blood VDRL and tests for rheumatoid factor and lupus erythematosus (LE) cells were negative. Gram staining of the pus taken from the pustules did not show any bacterium, and its culture was sterile. Histopathological study of an intact pustule showed a subcorneal pustule containing numerous neutrophils (Fig. 3) and diffuse macrophage granuloma in the dermis with a clear subepidermal zone. There were no histopathological features of vasculitis.

The dose of clofazimine was increased to 300 mg daily, and he was also given ibu-




FIG. 1. SCPD in a patient with lepromatous leprosy. Note numerous, tiny pustules on the forearms and upper arms and thickening of the earlobes.



FIG. 2. Close up view of the pustules which are oval, superficial and discrete.




FIG. 3. Histopathology showing a subcorneal pustule containing neutrophils ($\times 450$).

profen and cloxacillin orally. But the lepra reaction could not be controlled and the pustules and ENL lesions continued to erupt. Further, he developed paralysis of the ulnar nerve on the right side as evidenced by difficulty to adduct the medial two fingers of the right hand. He was then given oral prednisolone 40 mg daily along with antileprosy drugs. Within 48 hr of starting steroid therapy, his fever subsided and the pustules and ENL lesions started to regress. There was relief of his neuritic pain and, hence, the dose of prednisolone was gradually reduced and finally withdrawn in September 1991. There has been no recurrence of subcorneal pustules or ENL lesions, and the patient is now on antileprosy drugs alone.

The morphology and evolution of the pustules and their histopathological features suggested a diagnosis of subcorneal pustular dermatosis (SCPD) in our patient. The exact cause of SCPD is unknown. Recently, immunologic mechanisms have been implicated in its pathogenesis. Krogh and Tonder⁽⁴⁾ could detect antistratum corneum antibodies in two cases. Rarely SCPD may coexist with known autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis^(5,6). Bomb, *et al.*⁽²⁾ reported it in a patient with lepromatous leprosy and suggested that the autoantibodies to stratum corneum probably led to the development of SCPD in their patient.

In our patient, the development of SCPD simultaneously with the signs and symptoms of type 2 lepra reaction appears to be more than a chance occurrence. In addition to the clearly demonstrated mechanism of

the Arthus phenomenon, a possible auto-immune mechanism also has been suggested in the induction of reactions in lepromatous cases (3). Many serological findings confirm that the markers of autoimmune diseases are present in high titers during lepra reaction. These include rheumatoid factor, thyroglobulin antibody, and cold precipitable protein. The clinical features of type 2 lepra reaction often resemble autoaggressive connective tissue diseases (1). Thus, autoimmunity plays a major role in the development of SCPD as well as lepra reactions. So, the coexistence of SCPD and type 2 lepra reaction, as observed in our patient, appears to be more than fortuitous. Subsidence of both SCPD and ENL lesions following corticosteroid therapy further supports the view that both are induced by the same immunologic mechanism.

—K. Pavithran, M.D., D.V.D.

*Associate Professor
Department of Dermatology and
Venereology
Medical College Hospital
Kottayam 686 008, India*

REFERENCES

1. AZULAY, R. D. Autoaggressive hanseniasis. *J. Am. Acad. Dermatol.* **17** (1987) 1042–1046.
2. BUMB, R. A., KHULLAR, R. and MATHUR, N. K. Coexistence of subcorneal pustular dermatosis and lepromatous leprosy. *Indian J. Dermatol. Venereol. Leprol.* **51** (1985) 48–49.
3. DHARMENDRA and DESIKAN, K. V. Mechanisms of reactions. In: *Leprosy. Vol. 2*, Dharmendra, ed. Bombay: Samant and Company, 1985, pp. 984–998.
4. KROCH, H. K. and TONDER, O. Subcorneal pustular dermatosis: pathogenetic aspects. *Br. J. Dermatol.* **83** (1970) 429–434.
5. OLSEN, T. G., WRIGHT, R. C. and LESTER, A. I. Subcorneal pustular dermatosis and crippling arthritis. *Arch. Dermatol.* **115** (1979) 185–188.
6. SAULSBURY, P. T. and KESLER, R. W. Subcorneal pustular dermatosis and systemic lupus erythematosus. *Int. J. Dermatol.* **23** (1984) 63–64.


The Leprosy Game; a Health Education Tool

TO THE EDITOR:

Interaction, incentive, disincentive, and repetition are four factors the interplay of which influences the outcome of a learning experience in experimental as well as real life situations. All games have a scoring system which acts both as an incentive and a disincentive to the players. Repetitive playing sessions reinforce the rules and tricks that one needs to use in a winning strategy. Health education is an important factor in the control of leprosy (2). Cognizance must therefore be taken of the above principles of learning during the design and delivery of health education (1).

I have designed an indoor game suitable for health education purposes in leprosy (The Figure). The principles used can be manipulated to modify the game to suit other educational purposes as well; the training of paramedical workers springs to mind im-

mediately and, with intricate details, the teaching of medical students. The game attempts to make health education an enjoyable process.



THE FIGURE. Game board for "The Leprosy Game."